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Abstract Treatment of MCF-7 breast cancer cells with the
marine toxin maitotoxin (MTX) induces cell death. The
cytotoxic effects are clearly detectable within 2^4 h after cell
treatment with 10310^1039 M concentrations of MTX. The
response was found to depend on extracellular Ca2+, inasmuch as
cell death was prevented when culture dishes received MTX,
following addition of EGTA. MTX caused transient phosphor-
ylation of extracellular signal-regulated kinase isoforms 1 and 2
(ERK1 and ERK2) mitogen-activated protein kinase isoforms in
MCF-7 cells, which was maximal 15 min after toxin addition to
culture vessels. The effect was dependent on influx of extra-
cellular Ca2+, as it was abolished by EGTA, and was induced by
ionophores, such as A23187 and ionomycin. Our findings show
that signaling pathways involving Ca2+ ions may cause activation
of ERK1 and ERK2 in cell death responses.
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1. Introduction
Extracellular signal-regulated kinase isoforms 1 and 2
(ERK1 and ERK2) represent major members of the mito-
gen-activated protein kinase (MAPK) family of serine/threo-
nine protein kinases [1,2]. While activation of ERK1 and
ERK2 is usually linked to stimulation of cell proliferation,
evidence obtained in several experimental systems indicates
that these kinases can perform more complex regulatory func-
tions. Thus, kinase activity may be associated with inhibition
of cell proliferation and with cell death [1^10]. In these latter
cases, ERK activation has been found to occur through multi-
ple signaling pathways [1,2,5,6,8,9] or as a consequence of
inhibition of phosphoprotein phosphatases 1 and 2A
[3,4,7,10], suggesting that it might participate to death re-
sponses induced by a variety of agents, and attained by di¡er-
ent molecular mechanisms. Information regarding ERK acti-
vation in cytotoxic responses involving increased intracellular
levels of Ca2 ions, however, are lacking.
Maitotoxin (MTX) is a large (above 3 kDa) water-soluble
polyether compound produced by dino£agellates, such as
Gambieridiscus toxicus [11]. The toxic e¡ects of this agent
depend on its capacity to induce in£ux of extracellular Ca2
in both excitable and non-excitable cells [12]. Although a de-
tailed description of the mechanism of action of MTX is still
lacking, there is a substantial agreement on the contention
that stimulation of Ca2 in£ux would be mediated by both
voltage-dependent and receptor-operated Ca2 channels [12^
16].
Several events have been shown to occur as a consequence
of cell treatment with MTX, including increased phosphoino-
sitide turnover [17^19], translocation of protein kinase C from
the cytosolic to membrane compartment [19] and stimulation
of arachidonic acid release [20]. In di¡erent experimental sys-
tems, this type of signaling mechanism involves phosphoryla-
tion and consequent activation of MAPKs [21^23]. In keeping
with these observations, we have hypothesized that ERK ac-
tivation might participate to death responses induced by
MTX. In this report, we show that MTX is toxic in MCF-7
breast cancer cells, where it induces a transient, Ca2-depend-
ent activation of ERK1 and ERK2 isoforms.
2. Materials and methods
2.1. Materials
Peroxidase-linked anti-mouse and anti-rabbit Ig antibodies and the
ECL detection reagents were from Amersham. Tissue culture media
and reagents were from Life Technologies. MTX was prepared as
previously described [24]. The anti-ERK1 and anti-ERK2 antibodies
were from Santa Cruz. The anti-phospho-p44/42 MAPK antibodies
were obtained from New England Biolabs. The anti-E-cadherin anti-
body was a product from Zymed Laboratories. Pre-stained molecular
mass markers were obtained from Sigma. The nitrocellulose mem-
brane Protran B83 was obtained from Schleicher and Schuell. All
other reagents were of analytical grade.
2.2. Cell culture conditions and treatments
MCF-7 cells were grown in 5% carbon dioxide in air at 37‡C, in
90 mm diameter Petri dishes, with a culture medium composed of
Eagle’s MEM containing Earle’s salts, 1% non-essential amino acids
and 10% fetal calf serum, as previously described [25].
Stock solutions of MTX were prepared by dissolving the toxin in
50% ethanol. Cells in logarithmic growth received the tested com-
pound and paired cell dishes received vehicle. Cell processing to pre-
pare and analyze extracts was carried out at the end of individual
treatments at 37‡C, as speci¢ed below.
2.3. Preparation of cell extracts
Cells were harvested, washed three times with 20 mM phosphate
bu¡er, pH 7.4, 0.15 M NaCl (PBS) and were lysed by the addition of
either a hypotonic or a solubilization bu¡er. In the ¢rst case, cells
were dispersed in 1 ml of 20 mM Tris-HCl, pH 7.5, at 2‡C, 1 mM
EDTA and were lysed by sonication at 2‡C with two 8 s bursts, at an
output of 15 W. This total lysate was used to determine the DNA
content of cell suspensions, using the procedure of Labarca and Pai-
gen [26]. Cell lysis by a solubilization bu¡er was performed by dis-
persion in 0.5 ml PBS, containing 1% (v/v) NP-40, 0.5% (w/v) sodium
deoxycholate, 0.1% (w/v) SDS, 50 mM NaF, 10 mM Na4P2O7, 0.1 mg/
ml phenylmethylsulfonyl £uoride, 1 mM Na3VO4, 30 Wg/ml aprotinin,
and by two 10 s bursts of vortexing. Cell lysates were then subjected
to centrifugation for 30 min at 16 000Ug. The supernatants of this
centrifugation, operationally de¢ned cytosoluble extracts, were used
for colorimetric determinations of the protein content with bicincho-
ninic acid [27].
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2.4. Fractionation of proteins by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and immunoblotting
Cytosoluble extracts were brought to 2% SDS and 5% L-mercap-
toethanol, before being fractionated by SDS-PAGE, according to
Laemmli [28]. Samples containing the same amounts of protein were
fractionated using a 10% separating gel and a 3% stacking gel. After
completion of electrophoresis, proteins were electrophoretically trans-
ferred onto a nitrocellulose membrane, which was treated with 20 mM
Tris-HCl, pH 7.5, at 25‡C, 0.15 M NaCl, 0.05% (v/v) Tween 20 (im-
munoblotting bu¡er) containing 3% non-fat dry milk for 1 h at room
temperature. Membranes were then incubated for 1 h at room temper-
ature with immunoblotting bu¡er containing 1% non-fat dry milk and
primary antibody. When E-cadherin was analyzed, 1 mM CaCl2 was
included in every bu¡er employed in immunoblotting, up to the in-
cubation with the secondary antibody. After incubation, membranes
were washed ¢ve times with immunoblotting bu¡er and were incu-
bated for 1 h at room temperature with a peroxidase-linked secondary
antibody at a 1:3000 dilution in immunoblotting bu¡er containing 1%
non-fat dry milk. After washing, the membrane was developed by the
ECL detection system.
3. Results and discussion
Preliminary experiments were carried out to de¢ne the
MTX concentration to employ in our study. To this end,
we exploited the capacity of this compound to trigger cell
death and we then evaluated the e¡ect of increasing doses
of MTX on the cell content in culture dishes of proliferating
MCF-7 cells. The results we obtained showed that a 6 h treat-
ment with 5U10310 M MTX was su⁄cient to cause death of
about 50% of the cultured cells (Fig. 1).
We then checked whether Ca2 chelation, by addition of
EGTA to culture vessels, could inhibit the cytotoxic response
induced by MTX. This aspect was evaluated by measuring the
DNA content of cell cultures and by comparing the results
obtained with samples of MTX-treated cultures which had, or
had not, received EGTA before the addition of the toxin. The
results we obtained are reported in Fig. 2 and show that pre-
incubation of MCF-7 cells with EGTA actually prevented cell
losses from culture vessels, detected after 4^8 h of MTX treat-
ment.
The e¡ect of MTX on activation of MAPKs was next an-
alyzed by evaluating their phosphorylation state [1,2]. To this
end, we measured the time-course of the cellular content of
ERK1 and ERK2 isoforms, both as phosphorylated enzymes
and total protein, after MTX addition to MCF-7 cells. The
results we obtained by immunoblotting using speci¢c antibod-
ies (Fig. 3) showed that MTX treatment caused phosphoryla-
tion of ERK1 and, to a lesser extent, of ERK2, which was
maximal after 15 min of compound addition and decreased
thereafter, to become barely detectable after 1 h (upper panel).
Parallel measurement of ERK1 and ERK2 proteins in the
same extracts revealed that the levels of these enzymes were
not appreciably altered in the ¢rst 30 min of MTX treatment,
but a loss of these kinases could be detected by 1 h after toxin
addition (Fig. 3, center panel). In line with the toxic response
detected under our experimental conditions, involving cell de-
tachment from culture vessels, the measurement of a relevant
component involved in cell-cell adhesion of MCF-7 cells, such
as E-cadherin [29], revealed that MTX treatment induced cell
loss of this protein, which became undetectable after a 2 h
treatment with the toxin (Fig. 3, lower panel).
Fig. 1. E¡ect of MTX on proliferating MCF-7 cells. Cells in loga-
rithmic growth were treated with increasing concentrations of MTX
and cultures were maintained for 6 h at 37‡C before being proc-
essed and used for measurements of the DNA content, as described
under Section 2.
Fig. 2. E¡ect of EGTA on the cytotoxic response induced by MTX
in MCF-7 cells. Cells in logarithmic growth were pre-incubated for
15 min at 37‡C with 5 mM EGTA (triangles) or without any addi-
tion (circles) before receiving 0.5 nM MTX (closed symbols) or ve-
hicle (open circles) and the incubation was continued for the indi-
cated times at 37‡C. At the end of the incubations, cells were
processed and used for measurements of the DNA content, as de-
scribed under Section 2.
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The role of extracellular calcium in the induction of ERK1
and ERK2 phosphorylation by MTX was next ascertained by
analyzing the e¡ect of EGTA addition to cultured cells. As it
is shown in Fig. 4 (lane 2 of the upper panel), pre-incubation
of MCF-7 cells with EGTA did not a¡ect the basal phosphor-
ylation state of ERKs 1 and 2, but abolished the MTX-in-
duced increase of phosphorylated forms found 15 min after
toxin addition (Fig. 4, lanes 3 and 4 of the upper panel).
Furthermore, an increased phosphorylation of ERK1 and
ERK2 was observed when MCF-7 cells were treated with
other Ca2 permeants, such as ionomycin and the calcium
ionophore A23187 (Fig. 4, lanes 5 and 7 of the upper panel),
and this response could be abolished when MCF-7 cells re-
ceived EGTA before the addition of those compounds (Fig. 4,
lanes 6 and 8 of the upper panel). As the cell content of ERK1
and ERK2 protein was not appreciably a¡ected by those
treatments (Fig. 4, lower panel), our results showed that in-
duction of increased intracellular calcium concentrations was
the proximal trigger of ERK1 and ERK2 phosphorylation by
MTX in MCF-7 cells.
Detection of MAPK activation after MTX treatment has
not been reported so far. Our observations that increased
phosphorylation of ERK1 and ERK2 in MCF-7 cells is trig-
gered by other Ca2 permeants, and is prevented by EGTA,
indicate that the MTX-induced response is due to its function
as activator of Ca2 channels [12^16] and that an initial rise in
intracellular Ca2 would be su⁄cient to cause ERK phos-
phorylation in our experimental system. These ¢ndings are
similar to those reported for MAPK activation upon mem-
brane depolarization in PC12 cells [30]. In that experimental
system, the Ca2-dependent response was transient, whereas a
sustained activation was found after cell treatment with nerve
growth factor and it was shown that two di¡erent pathways
of MAPK activation exist in these excitable cells [30]. The
time-course we have measured for ERK phosphorylation
showed that the response is an immediate and transient event
also in MCF-7 breast cancer cells (Fig. 3). Thus, our ¢ndings
support the notion that Ca2 transiently activates MAPK
both in excitable and non-excitable cells [30^33].
In excitable cells, Ca2 activation of MAPK has been re-
lated to mechanisms controlling normal functioning, such as
neuronal plasticity [30]. The signi¢cance of the phenomenon
in non-excitable cells, instead, is presently unclear. In our
experimental system, ERK phosphorylation preceded cell
death (Fig. 2), indicating that it might play a role in toxic
responses induced by MTX in cultured cells. Furthermore,
as this response was elicited by other Ca2 permeants, and
was blocked by EGTA, our ¢ndings indicate that signaling
pathways involving Ca2 ions may cause activation of ERK1
and ERK2 in some cell death responses.
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